As a consequence, this initial increase in detection of more favorable PCa, could result in a reduced number of PCa cases to be detected, or progress to unfavorable PCa over the next 4–8 years [i.e., equivalent to the lead time for PCa through PSA testing/screening (29)]. This evidence concerns the gene KLK3 and posterior cortical atrophy.